
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EPRONTIA | Azurity | N-214679 RX | 2021-11-05 | 1 products, RLD, RS |
| TOPAMAX | Johnson & Johnson | N-020505 RX | 1996-12-24 | 4 products, RLD |
| TOPAMAX | Johnson & Johnson | N-020844 RX | 1998-10-26 | 2 products, RLD, RS |
| TROKENDI XR | Supernus Pharmaceuticals | N-201635 RX | 2013-08-16 | 4 products, RLD, RS |
| QUDEXY XR | Upsher-Smith Laboratories | N-205122 RX | 2014-03-11 | 5 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| eprontia | New Drug Application | 2025-03-21 |
| phentermine and topiramate | ANDA | 2025-06-24 |
| phentermine and topiramate extended-release | ANDA | 2025-05-21 |
| qsymia | New Drug Application | 2025-09-08 |
| qudexy | New Drug Application | 2025-02-07 |
| qudexy qudexy | New Drug Application | 2025-03-03 |
| qudexy qudexy | New Drug Application | 2025-04-10 |
| topamax | New Drug Application | 2025-03-24 |
| topiramate | ANDA | 2025-10-01 |
| topiramate tablets | 2009-04-03 |
Expiration | Code | ||
|---|---|---|---|
PHENTERMINE HYDROCHLORIDE / TOPIRAMATE, QSYMIA, VIVUS | |||
| 2025-06-24 | NPP | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Topiramate, Eprontia, Azurity | |||
| 11433046 | 2040-08-21 | U-3413, U-3414, U-3415 | |
| 11633374 | 2040-08-21 | DP | |
| Topiramate, Qudexy Xr, Upsher Smith Labs | |||
| 8652527 | 2033-03-19 | DP | |
| 8889190 | 2033-03-19 | DP | |
| 9101545 | 2033-03-19 | DP | |
| 9555005 | 2033-03-19 | DP | |
| 10363224 | 2033-03-19 | U-766 | |
| Phentermine Hydrochloride / Topiramate, Qsymia, Vivus | |||
| 8580299 | 2029-06-14 | U-3399 | |
| 8580298 | 2029-05-15 | DP | |
| 8895057 | 2028-06-09 | U-3398 | |
| 8895058 | 2028-06-09 | DP | |
| 9011905 | 2028-06-09 | DP | |
| 9011906 | 2028-06-09 | U-3398 | |
| Topiramate, Trokendi Xr, Supernus Pharms | |||
| 8298576 | 2028-04-04 | DP | U-106, U-1992 |
| 8298580 | 2027-11-16 | DP | U-106, U-1992 |
| 8663683 | 2027-11-16 | DP | U-106, U-1992 |
| 8877248 | 2027-11-16 | DP | U-106, U-1992 |
| 8889191 | 2027-11-16 | U-106, U-1992 | |
| 8992989 | 2027-11-16 | DP | U-1675, U-1992 |
| 9549940 | 2027-11-16 | DP | U-1675, U-1992 |
| 9555004 | 2027-11-16 | DP | U-1675, U-1992 |
| 9622983 | 2027-11-16 | DP | U-1675, U-1992 |
| 10314790 | 2027-11-16 | DP | U-1675, U-1992 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Drug common name | Topiramate |
| INN | topiramate |
| Description | Topiramate is a hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine. It has a role as an anticonvulsant and a sodium channel blocker. It is a cyclic ketal, a sulfamate ester and a ketohexose derivative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1 |
| PDB | — |
| CAS-ID | 97240-79-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL220492 |
| ChEBI ID | 63631 |
| PubChem CID | 5284627 |
| DrugBank | DB00273 |
| UNII ID | 0H73WJJ391 (ChemIDplus, GSRS) |










